BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23838349)

  • 1. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
    Burnett AK; Russell NH; Hunter AE; Milligan D; Knapper S; Wheatley K; Yin J; McMullin MF; Ali S; Bowen D; Hills RK;
    Blood; 2013 Aug; 122(8):1384-94. PubMed ID: 23838349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Faderl S; Ravandi F; Huang X; Garcia-Manero G; Ferrajoli A; Estrov Z; Borthakur G; Verstovsek S; Thomas DA; Kwari M; Kantarjian HM
    Blood; 2008 Sep; 112(5):1638-45. PubMed ID: 18565853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
    Burnett AK; Russell NH; Kell J; Dennis M; Milligan D; Paolini S; Yin J; Culligan D; Johnston P; Murphy J; McMullin MF; Hunter A; Das-Gupta E; Clark R; Carr R; Hills RK
    J Clin Oncol; 2010 May; 28(14):2389-95. PubMed ID: 20385984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
    Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
    Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
    Burnett AK; Russell NH; Hills RK; Kell J; Nielsen OJ; Dennis M; Cahalin P; Pocock C; Ali S; Burns S; Freeman S; Milligan D; Clark RE
    Leukemia; 2017 Feb; 31(2):310-317. PubMed ID: 27624670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
    Löwenberg B; Pabst T; Maertens J; van Norden Y; Biemond BJ; Schouten HC; Spertini O; Vellenga E; Graux C; Havelange V; de Greef GE; de Weerdt O; Legdeur MJ; Kuball J; Kooy MV; Gjertsen BT; Jongen-Lavrencic M; van de Loosdrecht AA; van Lammeren-Venema D; Hodossy B; Breems DA; Chalandon Y; Passweg J; Valk PJ; Manz MG; Ossenkoppele GJ;
    Blood; 2017 Mar; 129(12):1636-1645. PubMed ID: 28049642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.
    Selleslag D; Suciu S; Meloni G; Muus P; Halkes CJ; Venditti A; Ramadan SM; Pruijt H; Meert L; Vignetti M; Marie JP; Wittnebel S; de Witte T; Amadori S; Willemze R; Baron F
    Haematologica; 2017 Feb; 102(2):e47-e51. PubMed ID: 27789677
    [No Abstract]   [Full Text] [Related]  

  • 8. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
    Tran H; Yang D
    Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
    Alatrash G; Thall PF; Valdez BC; Fox PS; Ning J; Garber HR; Janbey S; Worth LL; Popat U; Hosing C; Alousi AM; Kebriaei P; Shpall EJ; Jones RB; de Lima M; Rondon G; Chen J; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1792-1800. PubMed ID: 27377901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
    Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH; Wheatley K; Milligan D
    J Clin Oncol; 2012 Nov; 30(32):3924-31. PubMed ID: 22851554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
    Buckley SA; Mawad R; Gooley TA; Becker PS; Sandhu V; Hendrie P; Scott BL; Wood BL; Walter RB; Smith K; Dean C; Estey EH; Pagel JM
    Br J Haematol; 2015 Aug; 170(3):349-55. PubMed ID: 25854284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
    Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
    Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
    Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
    Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
    Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
    Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
    Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
    Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; Maris M; Kovacsovics T; Goldberg S; Seiter K; Hari P; Greiner J; Vey N; Recher C; Ravandi F; Wang ES; Vasconcelles M; Huebner D; Kantarjian HM
    J Clin Oncol; 2012 Jul; 30(20):2492-9. PubMed ID: 22585697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
    Kantarjian HM; Erba HP; Claxton D; Arellano M; Lyons RM; Kovascovics T; Gabrilove J; Craig M; Douer D; Maris M; Petersdorf S; Shami PJ; Yeager AM; Eckert S; Abichandani R; Faderl S
    J Clin Oncol; 2010 Feb; 28(4):549-55. PubMed ID: 20026805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clofarabine in the treatment of elderly patients with acute myeloid leukemia.
    Aleem A; Anjum F; Algahtani F; Iqbal Z; Alsaleh K; Almomen A
    Asian Pac J Cancer Prev; 2013; 14(2):1089-92. PubMed ID: 23621192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.